Mercator Therapeutics and Pepscan Therapeutics sign research and licensing collaboration
Lelystad/Waltham – Dutch Pepscan Therapeutics NV has licensed its protein technology CLIPS to US-based in vivo phage display specialist Mercator Therapeutics. Under the term of the agreement, Pepscan will use its platform to optimize Mercator’s “Homing peptides”, peptide drugs that have been demonstrated in vivo to bind to receptors that are overexpressed on human tumours and induce internalization of both the peptide and the receptor. Pepscan’s CLIPS technology makes use of native or newly introduced cysteines in the amino acid sequence of the peptides of interest to make single, double or triple bridges to lock them into their biologically active conformation and to improve the drug candidates' stability. Pepscan will receive research funding, milestones, and royalties in connection with the development of multiple optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumour-killing payloads. Further financial details were not disclosed.